CROI 2014: HCV Abstract and Poster Presentation Coverage by Jules Levin (NATAP) – Updated March 26, 2014

21st Conference on Retroviruses and
Opportunistic Infections
Boston MA
March 3 - 6, 2014

Reported by Jules Levin

(All links open into new windows)

• The CORE HCV Cascade a Decade Later: Looking Ahead to an IFN-free Era - (03/24/14)
• High Hepatitis C Infection Rate in Birth Cohort Testing of an Urban, Primary Care Clinic Population: HCV Cascade, 8.2% Prevalence - (03/24/14)
• Impact of Rapid Hepatitis C testing on Receipt of Hepatitis C Results in a Public STD Clinic - (03/24/14)
• The burden of hepatitis C infection in Pennsylvania state prisons and implications for treatment - (03/24/14)
• Hepatitis C Virus Incidence in the Amsterdam Cohort Study among Men who have Sex with Men; 1984-2011 - (03/24/14)
• The Treatment Cascade for People with Chronic Hepatitis C Virus Infection in the United States - (03/24/14)
• Implementation of a Hepatitis C testing program in a network of Federally Qualified Health Centers: initial results of an Academic-Community partnership - (03/24/14)
• The Hepatitis C Cascade of Care Among HIV Infected Patients Following Diagnosis of HCV Infection - (03/24/14)
• CROI 2014 March 3 - Martin Delaney Panel: Hepatitis C Virus: From Trials and Tribulation to Triumph - (03/24/14)
• Safety and Efficacy of IFN-free, Sofosbuvir/RBV Therapy in HIV/HCV Liver Transplanted Patients - (03/24/14)
• Safety and Efficacy of IFN-free, Sofosbuvir/RBV Therapy in HIV/HCV Liver Transplanted Patients - (03/24/14)
• Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals - (03/24/14)
• Level of Alcohol Use and Advanced Hepatic Fibrosis in HIV-Infected and Uninfected Patients...."there may be no safe level of alcohol use among HIV+ & HCV+" - (03/24/14)
• Pill Burden and Treatment Duration Reduce Adherence to IFN-Free Hepatitis C Therapy in an Urban Cohort - (03/24/14)
• Telaprevir in Treatment-Experienced HIV-HCV G1 Coinfected Patients (ANRS HC26 TelapreVIH) - (03/24/14)
• Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BocepreVIH Trial - (03/24/14)
• Boceprevir/Telaprevir-Based Therapy in HIV-Infection: Interim Analysis of a Multicenter Cohort - (03/24/14)
• Telaprevir Increases Ribavirin Toxicity Through eGFR Decrease in HIV-HCV Coinfected Patients - (03/24/14)
• PHARMACOKINETICS OF FALDAPREVIR AND ANTIRETROVIRALS IN PATIENTS WITH HIV/HCV CO-INFECTION - (03/21/14)
• EFFECT OF FALDAPREVIR ON ATAZANAVIR PHARMACOKINETICS IN PATIENTS WITH HIV/HCV CO-INFECTION - (03/21/14)
• EFFECT OF FALDAPREVIR ON RALTEGRAVIR PHARMACOKINETICS IN HEALTHY VOLUNTEERS - (03/21/14)
• FIB-4 Alone Proves Best Predictor of ESLD in People With HCV/HIV - written Mark Mascolini - (03/21/14)
• Post-SVR Liver Decompensation Rate Similar With HCV/HIV and HCV Alone - written Mark Mascolini - (03/21/14)
• Post-Transplant Survival Lower With HIV and HCV-1 Than With HCV-1 Alone - written by Mark Mascolini - (03/12/14)
• Abbvie IFN-free 3 DAA Regimen in HCV Genotype 1-infected Pati ents on Methadone or Buprenorphine - (03/06/14)
• On-treatment Viral Response to MK-5172/MK-8742 ± RBV for 12 Weeks in HCV/HIV Co-infected Patients: The C-WORTHY Study - (03/06/14)
• ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage - (03/05/14)
• ABT-530, an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Genetic Barrier to Resistance - (03/05/14)
• All-Oral Combination of Daclatasvir, Asunaprevir, and BMS-791325 for HCV Genotype 1 Infection - (03/04/14)
• Daclatasvir in Combination With Simeprevir With or Without Ribavirin for Hepatitis C Virus Genotype 1 Infection - (03/04/14)
• All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1) - (03/04/14)
• Three-DAA Regimen (Abbvie) Achieves 99% SVR12 Rates in HCV Genotype 1b Naives - written by Mark Mascolini - (03/04/14)
• Simeprevir Plus PegIFN/RBV Yields 74% SVR12 in HCV/HIV Patients - written by Mark Mascolini - (03/04/14)
• SVR12 72% With Faldaprevir Plus PegIFN/RBV in Naives With HCV/HIV - written by Mark Mascolini - (03/04/14)
• Combination Oral, Hepatitis C Antiviral Therapy for 6 or 12 Weeks: Results of the SYNERGY Trial - (03/04/14)
• Simeprevir plus PegIFN/ribavirin in HCV genotype-1/HIV-1 co-infection (Study C212) - (03/04/14)
• Double or Triple DAA Therapy for HCV-1 Yields 95-100% SVRs in 6 or 12 Weeks (SYNERGY Study) - written by Mark Mascolini - (03/04/14)
• PEARL III: SVR ≥99% AFTER 12 WKS OF ABT-450/R/267 + ABT-333 ± RBV IN TREATMENT-NAIVE HCV GT1B INFECTION - (03/04/14)

Source NATAP